FOXO4-DRI 10mg

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of foxo4-dri 10mg in China. Welcome to wholesale bulk high quality foxo4-dri 10mg for sale here from our factory. Good service and reasonable price are available.

FOXO4-DRI 10mg is a cell permeability peptide antagonist, belonging to anti-aging peptides. Its core function is to induce apoptosis of aging cells by blocking the interaction between FOXO4 and p53, thereby clearing accumulated aging cells in the body and delaying the overall aging process. It is a transcription factor that is upregulated in senescent cells. It binds to the tumor suppressor protein p53, forming a complex that prevents p53 from inducing cell apoptosis and instead promotes cell aging (a self-protection mechanism of cell cycle arrest). The amino acid sequence of this substance simulates the key region in FOXO4 that binds to p53, but lacks the transcriptional activity of FOXO4. Therefore, it can competitively bind to p53, block the formation of FOXO4-p53 complex, release the apoptosis inducing function of p53, and promote aging cells to enter the apoptosis program. It can exhibit the ability to induce apoptosis of senescent cells in various cell lines, such as PDL9 cells and TM3 Leydig cells, but has no significant effect on non senescent cells. This specificity arises from the high expression of FOXO4-p53 interaction in senescent cells.

FOXO4-DRI  COA

Certificate of Analysis
Compound name	FOXO4-DRI
Grade	Pharmaceutical grade
CAS No.	2460055-10-9
Quantity	50g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090045
MFG	Jan 9th 2025
EXP	Jan 8th 2028
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.47%
Loss on drying	≤1.0%	0.28%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.90%
Single impurity	<0.8%	0.47%
Total microbial count	≤750cfu/g	80
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	400ppm
Storage	Store in a sealed, dark, and dry place below 2-8°C

FOXO4-DRI 10mg, as an anti-aging peptide targeting the clearance of senescent cells, mainly applies through its mechanism of blocking the interaction between FOXO4 and p53 and inducing apoptosis of senescent cells. It has demonstrated significant potential in anti-aging research, disease treatment, reproductive health, and fibrosis intervention.

The core mechanism of FOXO4-DRI is to competitively bind to p53, breaking the "defense mechanism" of senescent cells. Senescent cells inhibit apoptotic signals due to the binding of FOXO4 and p53, survive for a long time and secrete senescence-associated secretory phenotype (SASP), resulting in damage to the tissue microenvironment and organ function decline. FOXO4-DRI blocks this interaction, releases p53 to activate the mitochondrial apoptotic pathway, specifically inducing apoptosis of senescent cells, while having a relatively small impact on healthy cells. In animal models, FOXO4-DRI significantly reduces the expression of aging markers (such as β-galactosidase, p16Ink4a, p21), inhibits the release of SASP (such as IL-1α/β, TNF-α, MMP2), thereby alleviating tissue inflammation and damage. For example, in naturally aging mice, FOXO4-DRI by eliminating senescent interstitial cells in the testis reduces the release of SASP, improves the spermatogenic microenvironment, enhances the sperm quality and quantity of elderly mice, and restores the expression of testosterone synthesis-related proteins (3β-HSD, CYP11A1). In addition, FOXO4-DRI also promotes the proliferation of supporting cells, improving the spermatogenic ability and reproductive potential of aged animals.

The application of FOXO4-DRI in disease treatment mainly focuses on tumor treatment sensitization and fibrosis intervention. In tumor treatment, FOXO4-DRI induces apoptosis of tumor-associated senescent cells, inhibits the SASP in the tumor microenvironment, and reduces the invasive and metastatic ability of tumors. For example, FOXO4-DRI increases the sensitivity of non-small cell lung cancer and other tumor cells to radiotherapy, promotes apoptosis after radiotherapy, and reduces the ability of clone formation and cell migration. In fibrosis intervention, FOXO4-DRI activates the PI3K/AKT pathway, reduces oxidative stress, and reverses radiation or bleomycin-induced pulmonary fibrosis. In the rat model of radiation-induced pulmonary fibrosis (RIPF), FOXO4-DRI reduces collagen deposition in lung tissue, lowers the expression of col1α1 and α-SMA, and reduces the number of β-galactosidase-positive cells. In addition, FOXO4-DRI also inhibits the expression of P21 and P16Ink4a genes and proteins, as well as the expression of SASP genes (such as IL-1α, IL-1β, TNF-α and MMP2), thereby improving lung histology and respiratory function.

The application of FOXO4-DRI in the field of reproductive health mainly focuses on the insufficient testosterone secretion in aged male mice. As age increases, the testicular interstitial cells gradually age, resulting in a decline in testosterone synthesis capacity. FOXO4-DRI eliminates the aging interstitial cells in the testis, reduces the release of SASP, improves the spermatogenic microenvironment, thereby enhancing the sperm quality and quantity of aged mice. In addition, FOXO4-DRI also restores the expression of testosterone synthesis-related proteins (3β-HSD, CYP11A1), increases serum testosterone levels, and reduces the interstitial SA-β-gal activity. These findings provide potential strategies for the intervention of male delayed gonadal function decline.

The application of FOXO4-DRI in fibrosis intervention is not limited to pulmonary fibrosis, but also extends to liver and kidney fibrosis and other fields. Its mechanism mainly involves inhibiting myofibroblast differentiation and extracellular matrix deposition, thereby improving histology and function. For example, in the bleomycin-induced pulmonary fibrosis model, FOXO4-DRI also shows significant anti-fibrotic effects. In addition, FOXO4-DRI activates the PI3K/AKT pathway, reduces oxidative stress, and further alleviates fibrotic damage.

FOXO4-DRI 10mg is an anti-aging peptide designed based on the interaction mechanism between FOXO4 protein and p53. The manufacturing of its 10mg formulation involves key steps such as peptide synthesis, purification, quality control, packaging and storage.

Peptide Synthesis

 

The FOXO4-DRI is manufactured using the solid-phase peptide synthesis (SPPS) technique, which is the mainstream method in the field of peptide synthesis. This technique involves gradually adding amino acid residues onto a solid-phase carrier to form the target peptide chain. The amino acid sequence of FOXO4-DRI has been meticulously designed, with D-type amino acids being the main component. This design enhances the protease resistance and stability of the peptide, as well as improving its cell permeability. During the synthesis process, the amino acid connection at each step requires precise control of reaction conditions, such as temperature, pH value, and reaction time, to ensure the correct folding and purity of the peptide. Additionally, during the synthesis process, protecting groups need to be used to protect the side chain functional groups of amino acids, preventing unnecessary reactions during the synthesis process.

Key Points in the Manufacturing Process

01

Raw material selection

The manufacturing of FOXO4-DRI requires the use of high-quality amino acid raw materials. These raw materials need to undergo strict quality control to ensure their purity and quality meet the requirements.

02

Reaction condition control

During the synthesis process, the control of reaction conditions is crucial. Factors such as temperature, pH value, and reaction time all affect the synthesis efficiency and purity of the polypeptide. Therefore, during the manufacturing process, these conditions need to be precisely controlled to ensure the correct synthesis of the polypeptide.

03

Purification process optimization

The purification process is a key step in the manufacturing of FOXO4-DRI 10mg. By optimizing the purification conditions and methods, the purity and recovery rate of the polypeptide can be increased, and the manufacturing cost can be reduced.

04

Quality control is strict

Quality control is an important guarantee in the manufacturing process of FOXO4-DRI. Through strict quality control verification, the purity and quality of the polypeptide can be ensured to meet the requirements, thereby ensuring its biological activity and safety.

1. What are the main research objectives and the underlying principles of the technology?
A peptide molecule under research, designed to selectively interfere with specific protein interactions, in order to support cellular homeostasis and function.
2. How is the current research situation?
Currently, it is mainly in the preclinical and early research stages and has not yet been officially approved for market release by any national drug regulatory agency as a pharmaceutical product.
3. How to obtain and use?
It is currently only used for research purposes and is not available to the public. Any potential human applications must obtain approval in the future and be carried out under the strict guidance of professional medical personnel.

Hot Tags: foxo4-dri 10mg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, DecaPeptide 12 CAS 137665 91 9, Melanotan ii powder, Lpamorelin Powder CAS 170851 70 4, Tesamorelin CAS 218949 48 5, LONG R3 IGF I CAS 143045 27 6, CJC 1295 Peptide